Table 2.
Baseline clinical and pathological characteristics, by germline mutation status
| Characteristics | Patients with germline mutations (n = 28) | Patients without germline mutations (n = 111) | p value |
|---|---|---|---|
| Median age at diagnosis (IQR), yr | 63 (58–67) | 66 (60–71) | .025 |
| Median baseline PSA (IQR), ng/mL | 238 (98–407) | 100 (47–252) | .9 |
| Gleason grade group, n (%) | .99 | ||
| 1 | 0 (0) | 0 (0) | |
| 2 | 0 (0) | 3 (2.7) | |
| 3 | 3 (11) | 9 (8.1) | |
| 4 | 8 (29) | 38 (34) | |
| 5 | 17 (60) | 59 (53) | |
| Unknown | 0 (0) | 2 (1.8) | |
| Metastases volume,a n (%) | .11 | ||
| High volume | 23 (82) | 70 (63) | |
| Low volume | 5 (18) | 39 (35) | |
| Unknown | 0 (0) | 2 (1.8) | |
| PSA nadir within the first 7 mo of initial treatment, ng/mL | .7 | ||
| <0.2 | 5 (18) | 28 (25) | |
| 0.2–4 | 13 (46) | 47 (43) | |
| >4 | 10 (36) | 36 (32) | |
| Initial therapy regimen after diagnosis, n (%) | .4 | ||
| ADT only | 20 (71) | 80 (72) | |
| ADT + docetaxel | 6 (21) | 15 (14) | |
| ADT + abiraterone | 2 (7.1) | 16 (14) | |
| Family history of cancers, n (%) | 10 (36) | 31 (28) | .4 |
| Progression to mCRPC at the last follow‐up, n (%) | 24 (86) | 75 (68) | .058 |
a
High‐volume disease was defined as the presence of visceral metastases or ≥ 4 bone lesions with at least one outside of the vertebral column and pelvis according to the CHAARTED trial.
Abbreviations: ADT, androgen deprivation therapy; IQR, interquartile range; mCRPC, metastatic and castration‐resistant prostate cancer; PSA, prostate‐specific antigen.